Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus

Habib Yaribeygi, Mina Maleki, Thozhukat Sathyapalan, Tannaz Jamialahmadi, Amirhossein Sahebkar

Research output: Contribution to journalReview articlepeer-review


Type 2 diabetes mellitus (T2DM) is one of the main causes of mortality and morbidity worldwide. It leads to various long-term complications such as diabetic nephropathy. Diabetes nephropathy is the leading cause of renal failure in patients with chronic kidney diseases undergoing hemodialysis. Hence preventing the development and progression of diabetic nephropathy is one of the main goals in the management of patients with type 2 diabetes. Sodium-glucose cotransporter 2 inhibitors of empagliflozin is a potent anti-hyperglycemic agents. In addition, it has been shown to have some pharma-cologic potentials to provide renoprotective effects in patients with T2DM. In the current study, we review the available clinical data on the potential renoprotective effects of this drug from a mechanistic and molecular viewpoint.

Original languageEnglish
Pages (from-to)2850-2863
Number of pages14
JournalCurrent Medicinal Chemistry
Issue number25
Publication statusPublished - 2023


Dive into the research topics of 'Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus'. Together they form a unique fingerprint.

Cite this